Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5).

Robin F, Delmas J, Chanal C, Sirot D, Sirot J, Bonnet R.

Antimicrob Agents Chemother. 2005 Nov;49(11):4443-7.

2.

Syntheses, in vitro antibacterial and antifungal activities of a series of N-alkyl, 1,4-dithiines.

Zentz F, Labia R, Sirot D, Faure O, Grillot R, Valla A.

Farmaco. 2005 Nov-Dec;60(11-12):944-7. Epub 2005 Oct 18.

PMID:
16239002
3.

Syntheses, in vitro antibacterial and cytotoxic activities of a series of 3-substituted succinimides.

Zentz F, Le Guillou R, Labia R, Sirot D, Linard B, Valla A.

Farmaco. 2004 Nov;59(11):879-86.

PMID:
15544792
4.

Increased serum resistance in Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases.

Sahly H, Aucken H, Benedí VJ, Forestier C, Fussing V, Hansen DS, Ofek I, Podschun R, Sirot D, Tomás JM, Sandvang D, Ullmann U.

Antimicrob Agents Chemother. 2004 Sep;48(9):3477-82.

5.

Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study.

De Champs C, Chanal C, Sirot D, Baraduc R, Romaszko JP, Bonnet R, Plaidy A, Boyer M, Carroy E, Gbadamassi MC, Laluque S, Oules O, Poupart MC, Villemain M, Sirot J.

J Antimicrob Chemother. 2004 Sep;54(3):634-9. Epub 2004 Jul 28.

PMID:
15282240
6.

Factors associated with antimicrobial resistance among clinical isolates of Klebsiella pneumoniae: 1-year survey in a French university hospital.

De Champs C, Rich C, Chandezon P, Chanal C, Sirot D, Forestier C.

Eur J Clin Microbiol Infect Dis. 2004 Jun;23(6):456-62. Epub 2004 May 18.

PMID:
15148654
7.

Impairment of respiratory burst in polymorphonuclear leukocytes by extended-spectrum beta-lactamase-producing strains of Klebsiella pneumoniae.

Sahly H, Aucken H, Benedi VJ, Forestier C, Fussing V, Hansen DS, Ofek I, Podschun R, Sirot D, Sandvang D, Tomás JM, Ullmann U.

Eur J Clin Microbiol Infect Dis. 2004 Jan;23(1):20-6. Epub 2003 Dec 2.

PMID:
14652783
8.

Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum beta-lactamase CTX-M-9.

Aumeran C, Chanal C, Labia R, Sirot D, Sirot J, Bonnet R.

Antimicrob Agents Chemother. 2003 Sep;47(9):2958-61.

9.

Effect of D240G substitution in a novel ESBL CTX-M-27.

Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, De Champs C, Sirot J.

J Antimicrob Chemother. 2003 Jul;52(1):29-35. Epub 2003 May 29.

PMID:
12775683
10.

Inducible AmpC beta-lactamase of a new member Enterobacteriaceae.

Bonnet R, Chanal C, Ageron E, Sirot D, De Champs C, Grimont P, Sirot J.

Antimicrob Agents Chemother. 2002 Oct;46(10):3316-9.

11.

Prospective survey of beta-lactamases produced by ceftazidime- resistant Pseudomonas aeruginosa isolated in a French hospital in 2000.

De Champs C, Poirel L, Bonnet R, Sirot D, Chanal C, Sirot J, Nordmann P.

Antimicrob Agents Chemother. 2002 Sep;46(9):3031-4.

12.

[Enzymatic resistance of Escherichia coli to beta-lactams and clinical prevalence].

Lavigne JP, Sotto A, Merle C, Jourdan J, Soussy CJ, Sirot D.

Pathol Biol (Paris). 2002 Jul;50(6):388-93. French.

PMID:
12168257
13.

Synthesis and antimicrobial activities of N-substituted imides.

Zentz F, Valla A, Le Guillou R, Labia R, Mathot AG, Sirot D.

Farmaco. 2002 May;57(5):421-6.

PMID:
12058815
14.

Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis.

Bonnet R, Marchandin H, Chanal C, Sirot D, Labia R, De Champs C, Jumas-Bilak E, Sirot J.

Antimicrob Agents Chemother. 2002 Jun;46(6):2004-6.

15.

TEM derivative-producing Enterobacter aerogenes strains: dissemination of a prevalent clone.

Dumarche P, De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J.

Antimicrob Agents Chemother. 2002 Apr;46(4):1128-31.

16.
17.
18.

CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France.

Dutour C, Bonnet R, Marchandin H, Boyer M, Chanal C, Sirot D, Sirot J.

Antimicrob Agents Chemother. 2002 Feb;46(2):534-7.

19.

Plasmid-mediated TEM-3 extended-spectrum beta-lactamase production in Salmonella typhimurium in Casablanca.

AitMhand R, Soukri A, Moustaoui N, Amarouch H, ElMdaghri N, Sirot D, Benbachir M.

J Antimicrob Chemother. 2002 Jan;49(1):169-72.

PMID:
11751783
20.

Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly.

Bonnet R, Dutour C, Sampaio JL, Chanal C, Sirot D, Labia R, De Champs C, Sirot J.

Antimicrob Agents Chemother. 2001 Aug;45(8):2269-75.

21.

Inhibitor-resistant TEM-33 beta-lactamase in a Shigella sonnei isolate.

Sirot D, Chanal C, Bonnet R, De Champs C, Bret L.

Antimicrob Agents Chemother. 2001 Jul;45(7):2179-80. No abstract available.

22.

New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates.

de Champs C, Monne C, Bonnet R, Sougakoff W, Sirot D, Chanal C, Sirot J.

Antimicrob Agents Chemother. 2001 Apr;45(4):1278-80.

23.

Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study.

Sotto A, De Boever CM, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J.

J Clin Microbiol. 2001 Feb;39(2):438-44.

24.

A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group.

De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J.

Antimicrob Agents Chemother. 2000 Nov;44(11):3177-9.

25.

A novel class A extended-spectrum beta-lactamase (BES-1) in Serratia marcescens isolated in Brazil.

Bonnet R, Sampaio JL, Chanal C, Sirot D, De Champs C, Viallard JL, Labia R, Sirot J.

Antimicrob Agents Chemother. 2000 Nov;44(11):3061-8.

26.

A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil.

Bonnet R, Sampaio JL, Labia R, De Champs C, Sirot D, Chanal C, Sirot J.

Antimicrob Agents Chemother. 2000 Jul;44(7):1936-42.

27.

Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital.

Chanal C, Bonnet R, De Champs C, Sirot D, Labia R, Sirot J.

Antimicrob Agents Chemother. 2000 Jul;44(7):1930-5.

28.

Clinical relevance of Proteus mirabilis in hospital patients: a two year survey.

de Champs C, Bonnet R, Sirot D, Chanal C, Sirot J.

J Antimicrob Chemother. 2000 Apr;45(4):537-9.

PMID:
10747835
29.

Production of a TEM-24 plasmid-mediated extended-spectrum beta-lactamase by a clinical isolate of Pseudomonas aeruginosa.

Marchandin H, Jean-Pierre H, De Champs C, Sirot D, Darbas H, Perigault PF, Carriere C.

Antimicrob Agents Chemother. 2000 Jan;44(1):213-6.

30.

A method using TEM-5-beta-lactamase to assay imipenem.

Sotto A, Foulongne V, Sirot D, Jourdan J.

J Antimicrob Chemother. 1999 Dec;44(6):851-2. No abstract available.

PMID:
10590293
31.

Diversity of TEM mutants in Proteus mirabilis.

Bonnet R, De Champs C, Sirot D, Chanal C, Labia R, Sirot J.

Antimicrob Agents Chemother. 1999 Nov;43(11):2671-7.

32.

TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient.

Marchandin H, Carriere C, Sirot D, Pierre HJ, Darbas H.

Antimicrob Agents Chemother. 1999 Aug;43(8):2069-73.

33.

Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.

Chaïbi EB, Sirot D, Paul G, Labia R.

J Antimicrob Chemother. 1999 Apr;43(4):447-58. Review.

PMID:
10350372
34.

Inhibitor-resistant TEM beta-lactamases: revision of the TEM-41 sequence.

Labia R, Chaibi EB, Sirot D, Chanal-Claris C, Stapleton P, Shannon K, French G.

Antimicrob Agents Chemother. 1998 Oct;42(10):2771. No abstract available.

35.

Inhibitor-resistant OXY-2-derived beta-lactamase produced by Klebsiella oxytoca.

Sirot D, Labia R, Pouedras P, Chanal-Claris C, Cerceau C, Sirot J.

Antimicrob Agents Chemother. 1998 Sep;42(9):2184-7.

36.

[Extended spectrum beta-lactamases in Danish Klebsiella isolates].

Hansen DS, Sirot D, Kolmos HJ.

Ugeskr Laeger. 1998 Apr 6;160(15):2261-2. Danish.

PMID:
9599523
37.

Chromosomally encoded ampC-type beta-lactamase in a clinical isolate of Proteus mirabilis.

Bret L, Chanal-Claris C, Sirot D, Chaibi EB, Labia R, Sirot J.

Antimicrob Agents Chemother. 1998 May;42(5):1110-4.

38.

Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.

Chaibi EB, Péduzzi J, Farzaneh S, Barthélémy M, Sirot D, Labia R.

Biochim Biophys Acta. 1998 Jan 15;1382(1):38-46.

PMID:
9507060
39.

Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244.

Bret L, Chaibi EB, Chanal-Claris C, Sirot D, Labia R, Sirot J.

Antimicrob Agents Chemother. 1997 Nov;41(11):2547-9.

40.

A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.

Sirot D, Recule C, Chaibi EB, Bret L, Croize J, Chanal-Claris C, Labia R, Sirot J.

Antimicrob Agents Chemother. 1997 Jun;41(6):1322-5.

41.

Relationship between adhesion to intestinal Caco-2 cells and multidrug resistance in Klebsiella pneumoniae clinical isolates.

Di Martino P, Sirot D, Joly B, Rich C, Darfeuille-Michaud A.

J Clin Microbiol. 1997 Jun;35(6):1499-503.

42.

Novel extended-spectrum TEM-type beta-lactamase from an Escherichia coli isolate resistant to ceftazidime and susceptible to cephalothin.

Chanal-Claris C, Sirot D, Bret L, Chatron P, Labia R, Sirot J.

Antimicrob Agents Chemother. 1997 Mar;41(3):715-6.

43.

[Routine detection of beta-lactamases TEM resistant to inhibitors (IRT) and oxacillinases (OXA) in Escherichia coli].

Libert JM, Naudin F, Mougeot C, Sirot D.

Pathol Biol (Paris). 1997 Jan;45(1):34-40. French.

PMID:
9097844
44.

Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains.

Bret L, Chanal C, Sirot D, Labia R, Sirot J.

J Antimicrob Chemother. 1996 Aug;38(2):183-91.

PMID:
8877532
45.

Survey of prevalence of extended spectrum beta-lactamases among enterobacteriaceae.

Chanal C, Sirot D, Romaszko JP, Bret L, Sirot J.

J Antimicrob Chemother. 1996 Jul;38(1):127-32.

PMID:
8858464
46.

A new fimbrial antigen harbored by CAZ-5/SHV-4-producing Klebsiella pneumoniae strains involved in nosocomial infections.

Di Martino P, Livrelli V, Sirot D, Joly B, Darfeuille-Michaud A.

Infect Immun. 1996 Jun;64(6):2266-73.

47.

[Detection of pneumococci with reduced susceptibility to penicillin G using the ATB++STREP strip].

Romaszko JP, Chanal C, Sirot D, Sirot J.

Pathol Biol (Paris). 1996 May;44(5):355-7. French.

PMID:
8758475
48.

Problems encountered in the characterization of IRT beta-lactamase-producing clinical Escherichia coli isolates intermediate-resistant to cephalothin.

Chaibi EB, Farzaneh S, Morand A, Peduzzi J, Barthelemy M, Sirot D, Labia R.

J Antimicrob Chemother. 1996 Jan;37(1):190-1. No abstract available.

PMID:
8647764
49.

First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains.

Lemozy J, Sirot D, Chanal C, Huc C, Labia R, Dabernat H, Sirot J.

Antimicrob Agents Chemother. 1995 Nov;39(11):2580-2.

50.

Extended-spectrum plasmid-mediated beta-lactamases.

Sirot D.

J Antimicrob Chemother. 1995 Jul;36 Suppl A:19-34. Review.

PMID:
8543494

Supplemental Content

Support Center